Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

becton dickinson & co. - BDX

BDX

Close Chg Chg %
193.63 0.24 0.12%

Closed Market

193.87

+0.24 (0.12%)

Volume: 1.78M

Last Updated:

Dec 5, 2025, 3:59 PM EDT

Trade Now

Company Overview: becton dickinson & co. - BDX

BDX Key Data

Open

$193.72

 Day Range

193.69 - 196.12

52 Week Range

162.29 - 251.93

 Market Cap

$55.30B

Shares Outstanding

285.42M

 Public Float

284.92M

Beta

0.26

 Rev. Per Employee

N/A

P/E Ratio

33.28

 EPS

$5.84

Yield

214.91%

 Dividend

$1.05

EX-DIVIDEND DATE

Dec 8, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

2.44M

  

BDX Performance

1 Week
 
 -0.13%
 
1 Month
 
 8.95%
 
3 Months
 
 0.71%
 
1 Year
 
 -11.94%
 
5 Years
 
 -18.33%
 

BDX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About becton dickinson & co. - BDX

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

BDX At a Glance

Becton, Dickinson & Co.
1 Becton Drive
Franklin Lakes, New Jersey 07417-1880
Phone 1-201-847-6800 Revenue 21.84B
Industry Medical Specialties Net Income 1.68B
Sector Health Technology 2025 Sales Growth 8.237%
Fiscal Year-end 09 / 2026 Employees 72,000
View SEC Filings

BDX Valuation

P/E Current 33.282
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 32.181
Price to Sales Ratio 2.473
Price to Book Ratio 2.104
Price to Cash Flow Ratio 15.74
Enterprise Value to EBITDA 12.849
Enterprise Value to Sales 3.35
Total Debt to Enterprise Value 0.274

BDX Efficiency

Revenue/Employee 303,333.333
Income Per Employee 23,305.556
Receivables Turnover 7.295
Total Asset Turnover 0.388

BDX Liquidity

Current Ratio 1.113
Quick Ratio 0.645
Cash Ratio 0.103

BDX Profitability

Gross Margin 45.444
Operating Margin 15.476
Pretax Margin 8.613
Net Margin 7.683
Return on Assets 2.98
Return on Equity 6.544
Return on Total Capital 3.695
Return on Invested Capital 3.804

BDX Capital Structure

Total Debt to Total Equity 78.85
Total Debt to Total Capital 44.087
Total Debt to Total Assets 36.186
Long-Term Debt to Equity 72.174
Long-Term Debt to Total Capital 40.355
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Becton Dickinson & Co. - BDX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
18.87B 19.37B 20.18B 21.84B
Sales Growth
-6.81% +2.66% +4.16% +8.24%
Cost of Goods Sold (COGS) incl D&A
10.39B 11.20B 11.05B 11.91B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.10B 2.16B 2.14B 2.31B
Depreciation
672.00M 696.00M 676.00M 728.00M
Amortization of Intangibles
1.43B 1.47B 1.47B 1.59B
COGS Growth
-3.52% +7.78% -1.33% +7.80%
Gross Income
8.48B 8.17B 9.13B 9.93B
Gross Income Growth
-10.54% -3.62% +11.69% +8.77%
Gross Profit Margin
+44.92% +42.17% +45.22% +45.44%
2022 2023 2024 2025 5-year trend
SG&A Expense
5.96B 5.96B 6.05B 6.54B
Research & Development
1.26B 1.24B 1.19B 1.26B
Other SG&A
4.71B 4.73B 4.86B 5.28B
SGA Growth
- -3.88% +1.37% +8.20%
Other Operating Expense
(4.00M) 9.00M (9.00M) 2.00M
Unusual Expense
264.00M 339.00M 676.00M (5.00B)
EBIT after Unusual Expense
2.25B 1.86B 2.41B 8.38B
Non Operating Income/Expense
(67.00M) 257.00M 122.00M (5.89B)
Non-Operating Interest Income
16.00M 49.00M 163.00M 38.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
398.00M 452.00M 528.00M 613.00M
Interest Expense Growth
-15.14% +13.57% +16.81% +16.10%
Gross Interest Expense
444.00M 503.00M 585.00M 675.00M
Interest Capitalized
46.00M 51.00M 57.00M 62.00M
Pretax Income
1.78B 1.66B 2.00B 1.88B
Pretax Income Growth
-20.47% -6.79% +20.64% -6.18%
Pretax Margin
+9.45% +8.58% +9.94% +8.61%
Income Tax
148.00M 132.00M 300.00M 203.00M
Income Tax - Current - Domestic
49.00M 451.00M 149.00M 207.00M
Income Tax - Current - Foreign
228.00M 303.00M 362.00M 470.00M
Income Tax - Deferred - Domestic
(96.00M) (644.00M) (169.00M) (343.00M)
Income Tax - Deferred - Foreign
(33.00M) 22.00M (42.00M) (131.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.64B 1.53B 1.71B 1.68B
Minority Interest Expense
- - - -
-
Net Income
1.64B 1.53B 1.71B 1.68B
Net Income Growth
-21.85% -6.42% +11.44% -1.58%
Net Margin Growth
+8.66% +7.90% +8.45% +7.68%
Extraordinaries & Discontinued Operations
- - 144.00M (46.00M)
-
Discontinued Operations
- - 144.00M (46.00M)
-
Net Income After Extraordinaries
1.78B 1.48B 1.71B 1.68B
Preferred Dividends
- - 90.00M 60.00M
-
Net Income Available to Common
1.69B 1.42B 1.71B 1.68B
EPS (Basic)
5.9262 4.9741 5.8841 5.8335
EPS (Basic) Growth
-14.37% -16.07% +18.29% -0.86%
Basic Shares Outstanding
285.00M 286.28M 289.76M 287.65M
EPS (Diluted)
5.8776 4.9377 5.8589 5.8161
EPS (Diluted) Growth
-14.25% -15.99% +18.66% -0.73%
Diluted Shares Outstanding
287.36M 288.39M 291.01M 288.51M
EBITDA
4.62B 4.36B 5.23B 5.69B
EBITDA Growth
-14.54% -5.65% +20.06% +8.85%
EBITDA Margin
+24.47% +22.49% +25.92% +26.07%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 195.667
Number of Ratings 14 Current Quarters Estimate 2.811
FY Report Date 12 / 2025 Current Year's Estimate 14.869
Last Quarter’s Earnings 3.96 Median PE on CY Estimate N/A
Year Ago Earnings 14.40 Next Fiscal Year Estimate 15.812
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 12 12
Mean Estimate 2.81 3.37 14.87 15.81
High Estimates 2.85 3.64 14.97 16.25
Low Estimate 2.79 3.25 14.75 15.28
Coefficient of Variance 0.65 3.66 0.43 1.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 2
HOLD 9 10 10
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Becton Dickinson & Co. - BDX

Date Name Shares Transaction Value
Dec 3, 2025 Robert L. Huffines Director 180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 3, 2025 Jacqueline Wright Director 180 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Thomas E. Polen Chairman, CEO and President 105,471 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Christopher J. DelOrefice EVP & Chief Financial Officer 27,227 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Christopher J. DelOrefice EVP & Chief Financial Officer 22,982 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 David Shan EVP and Chief ISC Officer 8,079 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 David Shan EVP and Chief ISC Officer 9,104 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Michael D. Garrison EVP & Pres Med.Essntl&BioPharm 12,455 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Bilal Muhsin EVP & President Connected Care 21,751 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Roland Goette EVP and President, EMEA 17,222 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Roland Goette EVP and President, EMEA 17,360 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Roland Goette EVP and President, EMEA 16,123 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Thomas E. Polen Chairman, CEO and President 165,581 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Pavan Kumar Mocherla EVP & President, Greater Asia 5,763 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Thomas E. Polen Chairman, CEO and President 122,892 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Richard E. Byrd EVP & President Interventional 13,849 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 Richard E. Byrd EVP & President Interventional 15,568 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Richard E. Byrd EVP & President Interventional 13,183 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 2, 2025 Michael Feld EVP, CRO & Pres. Life Sciences 16,655 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00
Dec 2, 2025 David Shan EVP and Chief ISC Officer 8,970 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 0.00

Becton Dickinson & Co. in the News